ABSTRACT
Pediatric postacute sequelae of COVID-19 (pPASC), or long COVID, is a complex, heterogeneous, multisystem syndrome that leads to disruption in the lives of children and adolescents for months, and possibly years, after recovery from acute SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection. While the underlying pathophysiologic mechanisms of PASC are still under investigation, clinicians are facing the immediate challenges of treating these patients. In this article, we provide an overview of the current multidisciplinary evaluation of patients with pPASC. We also offer guidance on the medical, psychological, and rehabilitative management strategies based on experience with both pPASC and patients with other postviral syndromes. [Pediatr Ann. 2022;51(11):e421-e425.].
Subject(s)
COVID-19 , Adolescent , Child , Humans , COVID-19/therapy , SARS-CoV-2 , Disease Progression , Post-Acute COVID-19 SyndromeABSTRACT
Although children have been largely spared the most severe consequences of acute infection with SARS-CoV-2 virus, it is estimated that up to one-quarter of the more than 14 million children diagnosed as having coronavirus disease 2019 (COVID-19) have developed persistent symptoms of fatigue, postexertional malaise, neurologic and cognitive symptoms, and other symptoms that interfere with activities of daily living for months after their initial illness. Pediatric postacute sequelae of COVID-19 (pPASC), or long-COVID, is a complex, heterogeneous, postviral condition involving multiple body systems and is likely attributable to several concurrent underlying physiologic processes, including damage from direct viral invasion, endovascular dysfunction and microthrombosis, viral persistence, and the development of autoimmunity. In this review, we explore the current state of the literature regarding definition, epidemiology, clinical presentation, and proposed pathophysiologic mechanisms of pPASC. [Pediatr Ann. 2022;51(11):e416-e420.].